A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
← catalyst calendarNCT05112861 · readout ≤ 499 d
Sponsored by Outlook Therapeutics, Inc. (industry) · OTLK — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
120estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-11-15 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2021-11-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Age-Related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Wet Macular Degeneration
- BRVO - Branch Retinal Vein Occlusion
- Diabetic Macular Edema
Intervention
- Biological: bevacizumab — also filed as ONS-5010
Primary outcome
what the primary-completion date above is the date OFFrequency and incidence of treatment-emergent adverse events following intravitreal injections of ONS-5010 in vials or PFS
measured 3 months
Permalink · OTLK's whole pipeline · Catalyst calendar · Every registered study · What changed